Safety Evaluation of Lipid Nanoparticle–Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey

Veterinary Pathology

Volumn 55, Issue 2, 2018, Pages 341-354

  Sedic, Maja ^a   Senn, Joseph J ^a   Lynn, Andy ^a   Laska, Michael ^a   Smith, Mike ^a   Platz, Stefan J ^b   Bolen, Joseph ^c   Hoge, Stephen ^a   Bulychev, Alex ^a   Jacquinet, Eric ^a   Bartlett, Victoria ^d   Smith, Peter F ^e  

^a MODERNA THERAPEUTICS   (United States)

^b ASTRAZENECA   (United Kingdom)

^c PureTech Health ^*  (United States)

^d Akcea Therapeutics   (United States)

^e ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

drug discovery; lipid nanoparticle; modified mRNA; pharmacokinetics; toxicology

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT MEMBRANE ATTACK COMPLEX; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HISTAMINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID NANOPARTICLE; MESSENGER RNA; NANOPARTICLE; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ERYTHROPOIETIN; LIPID;

ACTIVATED PARTIAL THROMBOPLASTIN TIME; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERABILITY; ENDOCARDIAL HEMORRHAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HALF LIFE TIME; HEMATOCRIT; HEMATOPOIESIS; HISTOPATHOLOGY; LEUKOCYTE COUNT; MACACA FASCICULARIS; MALE; MAXIMUM CONCENTRATION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; RED BLOOD CELL DISTRIBUTION WIDTH; RETICULOCYTOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICOKINETICS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANIMAL; BLOOD CLOTTING; DRUG EFFECT; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; SPRAGUE DAWLEY RAT; VETERINARY MEDICINE;

ANIMALS; BLOOD COAGULATION; ERYTHROPOIETIN; FEMALE; HEMATOPOIESIS; INFUSIONS, INTRAVENOUS; LEUKOCYTE COUNT; LIPIDS; MACACA FASCICULARIS; MALE; NANOPARTICLES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 85042379069     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1177/0300985817738095     Document Type: Article

References (30)

1. Andrews DA, Boren BM, Turk JR. Dose-related differences in the pharmacodynamic and toxicologic response to a novel hyperglycosylated analog of recombinant human erythropoietin in Sprague-Dawely rats with similarly high hematocrit. Toxicol Pathol. 2013;42(3):524–539.
2. Andries O, McCafferty S, DeSmedt SC. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release. 2015;217:337–344.
3. Barros SA, Gollob JA. Safety profile of RNAi nanomedicines. Adv Drug Deliv Rev. 2012;64(15):1730–1737.
4. Casadevall N. Pure red cell aplasia and anti-erythropoietin antibodies in patient treated with epoetin. Nephrol Dial Transplant. 2003;18(8):viii37–viii41.
5. 3 H]-labeled siRNA in mice. Drug Metab Dispos. 2014;42(3):431–440.
6. Coelho T, Adams D, Silva A. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369(9):819–829.
7. Desmet CJ, Ishii KJ. Nucleic acid sensing at the interface between innate and adapted immunity in vaccination. Nat Rev Immunol. 2012;12(7):479–491.
8. Frost H. Antibody-mediated side effects of recombinant proteins. Toxicology. 2005;209(2):155–160.
9. Geall AJ, Verma A, Otten GR. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A. 2012;109(36):14604–14609.
10. Gilleron J, Querbes W, Zeigerer A. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol. 2013;31(7):638–646.
11. Gilmore IR, Fox SP, Hollins AJ. Delivery strategies for siRNA-mediated gene silencing. Curr Drug Deliv. 2006;3(2):147–155.
12. Islam MA, Reesor EK, Xu Y. Biomaterials for mRNA delivery. Biomater Sci. 2015;3(12):1519–1533.
13. Jeffs LB, Palmer LR, Ambegia EG. A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm Res. 2005;22(3):362–372.
14. Kariko K, Buckstein M, Ni H. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165–175.
15. Kariko K, Muramatsu H, Keller JM. Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol Ther. 2012;20(5):948–953.
16. Kormann MS, Hasenpusch G, Aneja MK. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biothechnol. 2011;29(2):154–157.
17. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2008;7(1):21–39.
18. Martins R, Queiroz JA, Sousa F. Ribonucleic acid purification. J Chromatogr A. 2014;1355:1–14.
19. Pardi N, Tuyishime S, Muramatsu H. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release. 2015;217:345–351.
20. Rozenski J, Crain PF, McCloskey JA. The RNA modifications database: 1999 update. Nucleic Acids Res. 1999;27(1):196–197.
21. Sahin U, Kariko K, Tureci O. mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759–780.
22. Semple SC, Akinc A, Chen J. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28(2):172–176.
23. Shatkin AJ. Capping of eukaryotic mRNAs. Cell. 1976;9(4, pt 2):645–653.
24. Sörgel F, Thyroff-Friesinger U, Vetter A. Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomized controlled trial. BMC Clin Pharmacol. 2009;9:10.
25. Thess A, Grund S, Mui BL. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Ther. 2015;23(9):1456–1464.
26. Tsongalis GJ. Branched DNA technology in molecular diagnostics. Am J Clin Pathol. 2006;126(3):448–453.
27. Wang Y, Su H, Yang Y. Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther. 2013;21(2):358–367.
28. Xue HY, Guo P, Wen WC. Lipid-based nanocarriers for RNA delivery. Curr Pharm Des. 2015;21(22):3140–3147.
29. Zangi L, Lui KO, von Gise A. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol. 2013;31(10):898–907.
30. Zimmermann TS, Lee AC, Akinc A. RNAi-mediated gene silencing in non-human primates. Nature. 2006;441(7089):111–114.